Biotech ProKidney LP will merge with a blank-check firm backed by veteran dealmaker Chamath Palihapitiya to go public in a deal valuing the combined entity at $2.64bn, the companies said on Tuesday.
The merger with Social Capital Suvretta Holdings Corp III will hand ProKidney up to $825 million in gross proceeds to advance the development of its treatment for chronic kidney diseases.
The proceeds include the $250 million the blank-check firm raised through an initial public offering (IPO) in July and a $575 million private investment in public equity, or PIPE.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
Investors in the PIPE include Palihapitiya’s Social Capital, Suvretta Capital’s healthcare-focused fund Averill and ProKidney’s existing shareholders.
ProKidney says its technology has the potential to treat chronic kidney diseases by using the patient’s own cells to restore organ function.
Often hailed as a “SPAC King”, Palihapitiya has sponsored some of the most high-profile blank-check deals including those for fintech SoFi Technologies Inc and home-selling platform Opendoor Technologies.
Source: Reuters
Can’t stop reading? Read more
PIF sells Al Hilal stake as Saudi league opens to private capital
PIF sells Al Hilal stake as Saudi league opens to private capital Saudi Arabia’s Public Investment...
TPG invests $100m in Zum at $1.7bn valuation to scale student mobility platform
TPG invests $100m in Zum at $1.7bn valuation to scale student mobility platform TPG has invested...
KKR and Apollo eye $2bn Logoplaste deal as sale process advances
KKR and Apollo eye $2bn Logoplaste deal as sale process advances KKR and Apollo are among private...